Blueprint's mastocytosis drug Ayvakit cleared for NHS use

NICE has recommended broad use of Blueprint Medicines' recently-approved therapy for rare blood disorder advanced systemic mastocytosis (ASM) by the NHS in England and Wales, including firs

Blueprint cashes in on the past to build its future

Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some of the royalties from its already-approved medicines in return for a cash injectio

Blueprint's latest approval for Ayvakit sets up clash with N...

Blueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), a group of rare blood cancers currently treated mainly by Novar

Blueprint pays the price of Ayvakit phase 3 miss as FDA reje...